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Objective: The aim of this study was to evaluate the efficacy, cardiotoxicity profile and long-
term benefits of neoadjuvant therapy in human epidermal growth factor receptor 2-positive 
operable breast cancer patients.
Patients and methods: A total of 142 patients diagnosed from 2005 to 2016 were included 
in the study. The treatment consisted of a sequential regimen of taxanes and anthracyclines 
plus trastuzumab. The clinical and pathological responses were evaluated and correlated with 
clinical and biological factors. The cardiotoxicity profile and long-term benefits were analyzed.
Results: The median age was 49 years, and 4%, 69% and 27% of patients had stage I, II and III 
breast cancer, respectively, while 10% had inflammatory breast cancer at diagnosis. Hormone 
receptor (HR) status was negative in 43%, and 62% had grade III breast cancer. The clinical 
complete response rate was 49% and 63% as assessed using ultrasound and magnetic reso-
nance imaging, respectively, and this allowed a high rate of conservative surgery (66%). The 
pathological complete response (pCR) rate was 52%, and it was higher in HR-negative (64%) 
patients than in HR-positive (41%) patients and in grade III breast cancer (53%) patients than 
in grade I–II breast cancer (45%) patients. Patients who achieved pCR had longer disease-free 
survival and a trend toward improved overall survival. A total of 2% of patients showed a 10% 
decrease in left ventricular ejection fraction to <50% during treatment. All patients except one 
recovered after discontinuation of trastuzumab.
Conclusion: A sequential regimen of taxanes and anthracyclines plus trastuzumab was effec-
tive, with high pCR rates and long-term benefit, and had a very good cardiotoxicity profile.
Keywords: neoadjuvant therapy, HER2-positive breast cancer, pathological complete response, 
cardiotoxicity, survival
Introduction
Neoadjuvant therapy (NT) is the standard of care for locally advanced and inflamma-
tory breast cancer.1–4
It is now known that it offers similar benefits like adjuvant therapy in terms of 
disease-free survival (DFS) and overall survival (OS),5,6 and so NT is currently imple-
mented for operable disease.
Currently, NT is generally used to improve surgical options, to determine the 
response to therapy, and it is expected to produce long-term benefits.
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Aggressive breast cancer subtypes benefit the most from 
primary systemic therapy: these include human epidermal 
growth factor receptor 2 (HER2)-positive and triple-negative 
tumors.7
In HER2-positive tumors, a combination of taxanes 
and anthracyclines plus trastuzumab has been the standard 
treatment.8–13
Trastuzumab interacts with the extracellular domain of 
HER2 and inhibits signaling from HER2 homodimers more 
effectively than from HER2 heterodimers with EGF recep-
tor 1 (HER1) or EGF receptor 3 (HER3). This results in the 
downregulation of the phosphatidylinositol-3 kinase (PI3K) 
pathway and cell apoptosis. Trastuzumab can also induce 
antibody-dependent cellular cytotoxicity.14–16
Despite the advance in the knowledge of HER2-positive 
tumors and improvements in treatments, a small percentage 
of patients still suffer from recurrence and die.
Many mechanisms underlying resistance to anti-HER2 
therapies have been studied. They include three major groups. 
The first group involves the concept of “redundancy”. Exam-
ples include the inhibition of the incomplete receptor family 
by a truncated form of the HER2 receptor (p95-HER2) and 
the lack of exon 16 in the extracellular domain of the HER2 
receptor (D16 isoform).
The second major group involves “reactivation”. Exam-
ples include the deregulation of the PI3K pathway because 
of mutations in PI3K catalytic subunit or reduced levels of 
phosphatidylinositol-3,4,5-triphosphate 3-phosphatase. The 
third group involves the concept of “scape”. This involves 
the use of other pathways that can preexist or be acquired at 
the time of resistance. An example is the cross talk between 
the estrogen receptor and the HER2 pathways.
Other mechanisms of resistance to anti-HER2 therapies 
are being studied and include regulators of cell cycle and 
apoptosis, the tumor microenvironment and immune system, 
mucins and various receptors and tyrosine kinases.17,18
However, combinations of targeted agents represent a 
way to reduce resistance to trastuzumab.
In recent years, we have observed that dual blockade of 
the HER2 pathway produces better results with an increase in 
pathological complete response (pCR) rates. In the Neosphere 
trial, pertuzumab plus trastuzumab and chemotherapy dem-
onstrated higher pCR rates compared with the trastuzumab 
or pertuzumab arms, and these pCR rates were associated 
with better DFS.19–24
Lapatinib was studied in this context in combination 
with trastuzumab and chemotherapy in several clinical tri-
als. Although some trials of the combination showed higher 
pCR rates, they did not demonstrate statistically significant 
long-term benefits. In addition, lapatinib was associated with 
a worse toxicity profile.25–29
It is known that the response to treatment depends on 
clinical factors such as lower stage at diagnosis (small tumors 
and few or no metastatic axillary nodes) and biological factors 
such as negative hormone receptor (HR) status, high ki-67 
percentage and grade II–III tumors.30–32
The association between clinical and pathological 
response has been studied in the neoadjuvant setting. The best 
imaging methods, such as ultrasound or magnetic resonance 
imaging (MRI), to monitor tumor shrinkage during treat-
ment33–38 and their correlation with pathological response 
have also been analyzed.39
pCR has been associated with long-term benefits, DFS 
and OS, in several clinical trials and meta-analyses,7,40 but 
controversies exist on this point. Some authors consider 
pCR a surrogate end point that has yet to demonstrate a real 
long-term benefit.41,42
The sequential administration of a taxane and an anthra-
cycline plus trastuzumab provides a significant benefit to 
patients with a high pCR rate.43 The cardiotoxicity associ-
ated with this anthracycline plus trastuzumab combination 
is a drawback,44–46 but formulations such as epirubicin or 
liposomal anthracyclines have reduced this negative impact 
on heart function.47,48 Although it is still important to monitor 
left ventricular ejection fraction (LVEF) during treatment, 
improved knowledge of long-term cardiotoxicity years after 
the end of treatment is needed.21
We analyzed the efficacy data, cardiotoxicity and long-
term follow-up in 142 patients with HER2-positive breast can-
cer tumors diagnosed from 2005 to 2016 at a single institution 
who were treated homogenously through sequential admin-
istration of a taxane and an anthracycline plus trastuzumab.
Patients and methods
This is a retrospective observational study that included 142 
patients with stage I–III HER2-positive breast cancer tumors 
diagnosed from 2005 to 2016 at a single institution.
The study, as well as all procedures performed in the study, 
was approved by the ethics committee of the Galician region 
(Comité Autonómico de Ética de Investigación de Galicia, 
Spain) in 2015 with the code: SAN-TRA-2015-01, and all the 
patients who were alive at the time the retrospective study was 
started provided written informed consent for participation.
The study procedures were carried out in accordance 
with the 1975 Declaration of Helsinki, as revised in 2000, 
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neoadjuvant therapy in breast cancer
Patients
All patients included were ≥18 years of age and had Eastern 
Cooperative Oncology Group Performance Status of ≤1.
Histological type, tumor grade, ki-67 index, estrogen and 
progesterone receptor and HER2 status were determined 
locally using pretreatment core biopsies.
HER2-positive breast cancer was considered if the tumors 
exhibited threefold overexpression of the HER2 receptor as 
assessed using immunohistochemical techniques (Hercept-
estTM Dako until 2013 and Roche until 2016) or a threefold 
overexpression of the HER2 gene as assessed using fluores-
cent (until 2013) or silver (2013–2016) in situ hybridization 
(in the same laboratory) in accordance with 2007 and 2013 
American Society of Clinical Oncology/College of American 
Pathologist guidelines.49,50
An ultrasound-guided fine-needle puncture aspiration 
was also performed on suspected malignant axillary lymph 
nodes at diagnosis.
The tumor site was marked using a stainless steel marker 
placed using ultrasound guidance in the majority of patients. 
Multicentric or inflammatory tumors were not marked 
because of the indication for mastectomy despite the response 
to treatment.
From 2005 to 2012, a sentinel lymph node biopsy (SLNB) 
was performed prior to treatment in patients with clinically 
negative axilla, and from 2012 to 2016 this procedure was 
performed after treatment.51,52
At diagnosis, patients were free from cardiovascular 
disease and demonstrated adequate cardiac function with an 
LVEF >50%, as measured using echocardiography.
This echocardiography was repeated after three to 
four cycles, at the end of chemotherapy and during the 
follow-up period, at least 6 months after the end of adjuvant 
trastuzumab.
Patients also had adequate hematological, renal and 
hepatic function.
The different treatment regimens administered are shown 
in Figure 1. The vast majority of patients received a total of 





















Figure 1 Types of chemotherapy.
Notes: *Chemotherapy doses. Paclitaxel: 80 mg/m2, weekly ×12 doses. FEC: 5-fluorouracil: 600 mg/m2/epirubicin: 75 mg/m2/cyclophosphamide: 600 mg/m2 every 3 weeks × 
four cycles. Myocet: 60 mg/m2/cyclophosphamide: 600 mg/m2/every 3 weeks × four cycles. T: 8 mg/kg IV loading dose followed by 6 mg/kg IV every 3 weeks (a total of 
12 months, including in the neoadjuvant and adjuvant setting).
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Physical examinations were performed every 3 weeks 
during chemotherapy treatment. Mammograms, ultrasound 
and MRI were performed before and after neoadjuvant 
treatment.
The clinical response (CR) was measured through physi-
cal examination and MRI in accordance with the response 
evaluation criteria in solid tumors.53,54
Patients underwent surgery between 3 and 5 weeks from 
the end of chemotherapy. There was an increase in conser-
vative breast surgery in patients that were candidates for 
mastectomy at diagnosis.
pCR was defined as the total absence of invasive tumor 
in both breast and axillary nodes (ypT0/is ypN0).
The pathological response was measured in accordance 
with the Miller and Payne system in most patients.55
We used the revised American Joint Committee on Can-
cer TNM system in patients included in the first 2 years of 
the study.56
This pathological response was correlated with clinical 
and biological factors (tumor size, axillary nodes, HR status 
and ki-67 index).
All patients treated using conservative breast surgery 
received whole-breast irradiation at a standard dose. Some 
patients with T3 tumors at diagnosis were also irradiated after 
mastectomy. Regional nodal irradiation of the supraclavicular 
fossa-axillary apex was used in patients with clinical stage III 
disease, in patients with four or more positive lymph nodes and 
in selected patients with one to three positive lymph nodes.57,58
After completion of systemic and local therapy, patients 
with HR-positive tumors received tamoxifen or an aromatase 
inhibitor if the patient was menopausal.
We report DFS (defined as the time from surgery to the 
first documented disease progression) and OS (time from 
surgery to death).
statistical analyses
We performed a descriptive analysis for all variables. Con-
tinuous variables were reported using the median as the 
central value and the SD. For dichotomous or categorical 
variables, absolute numbers and percentages were computed. 
The chi-squared two-tailed test was used for comparative 
analyses between categorical variables.
We estimated DFS and OS rates for each group using the 
Kaplan–Meier method. A comparison of survival curves was 
performed using the log-rank test. Differences in survival 
between groups were compared using the Cox regression 
test. All statistical tests were two sided, and a significance 
level of 0.05 was applied.
Results
A total of 142 patients with stage I–III HER2-positive 
breast cancer tumors, who were candidates for primary 
systemic therapy and were diagnosed from 2005 to 2016 at 
our institution, were included in the study. The pretreatment 
characteristics of the patients are listed in Table 1.
The median patient age was 49 (30–79) years, with stage 
I, II or III breast cancer at diagnosis in 4%, 69% and 27%, 
respectively. A total of 10% of patients had inflammatory 
breast cancer, 43% of tumors were HR negative and 62% 
were grade III, while 90% of tumors were confirmed to be 
HER2 positive through immunohistochemistry (threefold 
increase in protein expression) and the rest through fluores-
cent in situ hybridization or silver in situ hybridization. A 
Table 1 Patient characteristics




















ihC 3+ 128 (90)











surgical indication at diagnosis
Mastectomy 120 (84)
Tumorectomy 22 (16)
Note: aOne patient had a nonmeasurable lobular tumor, and another had an occult 
carcinoma.
Abbreviations: cT, clinical tumor size; FISH, fluorescent in situ hybridization; HR, 
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neoadjuvant therapy in breast cancer
total of 84% of patients had an indication for mastectomy 
at diagnosis.
A total of 98% of patients completed the planned cycles 
of chemotherapy. The remaining 2% (three patients) could 
not complete chemotherapy because of hepatotoxicity in one 
patient, sustained grade III asthenia and grade II neutropenia 
in an elderly patient and a massive pulmonary thromboem-
bolism in the third patient after four cycles of chemotherapy.
Clinical response
The CR was assessed through mammography, ultrasound 
imaging and MRI before and after systemic therapy and 
immediately before surgery in most patients.
In the first years of the study, breast MRI was not a rou-
tine imaging technique, so it was not performed in the first 
18 patients.
The CR data are listed in Table 2.
A total of 49% and 63% of patients demonstrated a clini-
cal complete response, as measured through ultrasound and 
MRI, respectively.
Pathological response
The pCR rate, defined as the total absence of invasive tumor 
in both breast and axillary nodes (ypT0/is ypN0), was 52%. 
The pCR rates in breast, breast and axilla and in different 
subgroups are summarized in Tables 3 and 4.
The pCR rate was higher in ductal (53%) than in lobular 
(14%) cancer, in HR-negative (64%) than in HR-positive 
(41%) cancer, in grade III (53%) than in grade I–II (45%) 
cancer and in tumors with a ki-67 value >20 (85%) than in 
those with a ki-67 value <20 (15%).
A total of 61% and 68% of patients with CR, as assessed 
using ultrasound and MRI, respectively, also demonstrated 
pCR.
pCR was higher in patients treated using paclitaxel/
trastuzumab (PT) followed by Myocet/cyclophosphamide/
trastuzumab (54%) than those treated using PT followed 
by fluorouracil/epirubicin/cyclophosphamide/trastuzumab 
(38%), but the numbers of patients assigned to each group 
were too low to result in statistically significant differences.
surgery
At diagnosis, 84% of patients were indicated for mastectomy. 
After treatment, tumorectomy was performed in 66%.
Axillary dissection, SLNB and no axillary procedure were 
performed in 69%, 22% and 9% of patients, respectively. 
Table 2 Complete response
CR
(n=142)












not evaluable 23 (16)
Notes: aMRI was performed in 124 patients. Not evaluable, nonmeasurable disease 
or not performed.
Abbreviations: CR, complete response; MRI, magnetic resonance imaging; PD, 
progressive disease; PR, partial response; SD, stable disease.
Table 3 pCR in breast and breast/axilla
 Breast and axilla
n (%)
Breast (without axillary pCR)
n (%)
pCr
(n=79) 72 (52) 7 (5)
Abbreviation: pCR, pathological complete response.








<5 cm 41 (50) 41 (50)
>5 cm 16 (57) 12 (43)
nodes
Positive 47 (46) 56 (54)
negative 25 (64) 14 (36)
histological subtype
Ductal 69 (53) 62 (47)
lobular 1 (14) 6 (86)
Others 2 (50) 2 (50)
hr
negative 39 (64) 22 (36)
Positive 33 (41) 48 (59)
Ki-67
<20 11 (15) 13 (19)
20–35 21 (29) 29 (41)
>35 40 (56) 28 (40)
grade
i 0 (0) 1 (100)
ii 18 (45) 22 (55)
iii 42 (53) 37 (47)
Type of chemotherapy
Pac-T-FeC-T 13 (38) 21 (62)
Pac-T-Myocet-T 44 (54) 37 (46)
Others 15 (56) 12 (44)
Abbreviations: 5-FEC, 5-fluorouracil–epirubicin–cyclophosphamide; HR, hormone 
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Those patients with a negative SLNB before treatment did 
not undergo an axillary procedure.
Long-term efficacy data
At the time of the analysis in March 2018, and with a median 
follow-up of 55 months, 27 patients suffered from breast can-
cer recurrence and 15 patients died as a result of any cause.
DFS and OS curves are shown in Figures 2 and 3, 
respectively. We were able to demonstrate an association 
between pCR and better DFS with statistical significance 
(P=0.19) and a trend toward improved OS (P=0.068; Fig-
ures 4 and 5).
Cardiotoxicity
Because of the potential cardiotoxicity associated with 
anthracyclines and trastuzumab, knowledge of cardiovascu-
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Figure 2 DFs assessed using the Kaplan–Meier method.



















Figure 3 Os assessed using the Kaplan–Meier method.
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neoadjuvant therapy in breast cancer
Age at diagnosis, body mass index (BMI), arterial hyper-
tension, dyslipidemia, preexisting cardiovascular disease and 
previous radiotherapy are recognized as risk factors for heart 
disease in breast cancer patients treated using anthracyclines 
and trastuzumab.59–65
The risk factors for developing a cardiac event in the 
current cohort of patients are listed in Table 5.
At diagnosis, all patients had adequate cardiac function 
with an LVEF of >50%, as measured using echocardiography.
The echocardiography was repeated after chemotherapy 
treatment and during follow-up at least 6–12 months after 
the end of adjuvant trastuzumab in 70% of patients.
At the end of chemotherapy treatment, five patients 
suffered a decline in LVEF <50% (3.5% of patients). The 
 cardiovascular risk factors for these patients are listed in 
Table 6.
Of these patients, four did not experience cardiac symp-
toms and demonstrated a rapid recovery after temporarily 
stopping trastuzumab. One did not receive adjuvant trastu-
zumab. Three received left breast radiotherapy and two had 
a history of high blood pressure.
The fifth patient who suffered a decline in LVEF below 
50% did not receive adjuvant trastuzumab and developed 
severe ventricular dysfunction over subsequent years.
This patient had a high BMI and received left breast 
radiotherapy, which are risk factors for heart disease.
LVEF at baseline, end of chemotherapy and beyond 6 
months from the end of trastuzumab treatment is shown in 
Figure 6.
Discussion
Although clear clinical and preclinical evidence for dual 
blockade of the HER2 pathway in neoadjuvant treatment of 
HER2-positive breast cancer has been reported and this has 
become a standard approach in combination with chemo-


















Log-rank (Mantel–Cox) 5,516 1 0.019
gl Sig.
Figure 4 DFs based on pCr.
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benefit from the addition of the second biological inhibi-
tor to their chemotherapy regimen, and what is the role of 
anthracyclines and cardiotoxicity?
Considering that we retrospectively analyzed a homoge-
neous population treated using a taxane and anthracycline 
concomitantly with trastuzumab and all treatment was adminis-
tered before surgery, the median pCR (total absence of invasive 
tumor in both breast and axillary nodes) achieved in our cohort 
was high (52%) and is comparable to other treatment series 
employing a similar sequence. In a previous study, Buzdar et 
al11 used sequential 5-fluorouracil–epirubicin–cyclophospha-
mide (FEC) and paclitaxel with trastuzumab and achieved a 
higher pCR (56%), but only evaluated pCR in the breast.
The median pCR achieved in studies employing dual 
blockade of the HER2 pathway ranges from 45% to 62%. 
In the most important of these studies (Neosphere and Try-
phaena), only pCR in the breast was evaluated.
It is known that the combination of anthracyclines and 
trastuzumab is very active, but it can increase cardiotoxic-
ity. There are anthracyclines such as epirubicin or liposomal 
formulations that can reduce this toxicity.
A Phase III trial reported that adding trastuzumab to 
epirubicin does not improve efficacy in terms of pCR in a 
sequence with taxane and trastuzumab vs epirubicin alone 
using the same sequence. However, long-term efficacy and 
cardiotoxicity data are needed to draw robust conclusions.10
In the current study, 37 patients were treated with epiru-
bicin and 85 with liposomal doxorubicin (Myocet®; Teva B.V, 
Haarlem, the Netherlands), achieving a higher pCR rate in 
the Myocet group (38% and 51%, respectively). The number 
of patients assigned to each group was too low to produce 
statistically significant differences.
These rates are comparable to those in other published 

















Log-rank (Mantel–Cox) 3,342 1 0.068
gl Sig.
Figure 5 Os based on pCr.
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neoadjuvant therapy in breast cancer
evidence to support the use of liposomal anthracyclines in the 
neoadjuvant setting. Most published series uses concomitant 
administration of chemotherapeutics instead of sequential 
administration and a higher number of cycles.48,66–68
We identified three biological factors associated with a 
better response to therapy: HR-negative status, ki-67 >20% 
and grade III breast cancer.
The high pCR achieved in the HR-negative patients vs the 
HR-positive patients was also seen in previous clinical trials in 
the HER2 neoadjuvant setting,19,26,69 and this could be explained 
by the cross talk between the HER2 and endocrine pathway 
conferring resistance to agents targeting either pathway.
Many studies have demonstrated the prognostic and pre-
dictive value of ki-67, whereby it is used to identify patients 
who will benefit most from systemic therapy. These studies 
used different methods for scoring this proliferation antigen 
and included a heterogeneous population with different 
biological subtypes.70,71
A 20% cutoff point for the ki-67 index appears to be 
a statistically significant prognostic factor in luminal B 
HER2-negative tumors. The median value of ki-67 is usu-
ally higher in triple-negative and HER2-positive tumors. 
Median ki-67 values of 35%–40% in HER2-positive and 
50% in triple-negative breast cancer have been previously 
reported.72
In the current study, we examined three different cutoff 
points for the ki-67 index and their relationship with pCR, 
DFS and OS.
Tumors with ki-67 >20% (especially those >35%) 
achieved higher pCR rates, but no group was correlated with 
long-term benefits.
The correlation between histological grade and prog-
nosis has been confirmed in multiple reports and currently 
helps clinicians to make treatment decisions.73–78 Its value 
as an independent factor to predict the response to NT is 
unclear.30,31 In the current series, grade III tumors achieved 
a higher pCR rate compared with grade I–II tumors.
There was a high rate of indication for mastectomy at 
diagnosis in the current series. This could be explained by the 
incidence of T3 and T4 tumors and the relationship between 
breast/tumor size in T2 tumors.
After systemic treatment, the rates of breast conservation 
were also high and greater than in other previously reported 
series.79–81 We attributed this to the high pCR achieved in this 
selected HER2 population.
The potential for an increase in local recurrence after 
NT followed by breast conservation was analyzed in several 
studies and meta-analyses.5,82 The MD Anderson Prognos-
tic Index concludes that the local recurrence rate could 
depend on other biological factors such as clinical N2 or 
N3 disease, lymphovascular space invasion, a multifocal 
pattern of residual disease and a residual pathological pri-
Table 5 Risk factors for cardiac events




age at diagnosis (years)  
<50 77 (54)
50–59 31 (22)
≥60 years 34 (24)












left breast radiotherapy  
Yes 78 (55)
no 64 (45)
Type of anthracyclines  
epirubicin 34 (24)
Liposomal doxorubicin 86 (61)
Classic doxorubicin 22 (15)
Note: aBMI: 25–30, overweight; >30, obese.
Abbreviation: BMI, body mass index.
Table 6 Cardiovascular risk factors in patients who suffered a decline in LVEF <50%
 Age at 
diagnosis
BMI >25 Arterial 
hypertension




Patient 1 57 no no no no epirubicin
Patient 2 44 Yes no no Yes Myocet
Patient 3 54 Yes Yes no Yes Myocet
Patient 4 73 Yes Yes no Yes Myocet
Patient 5 63 no no no Yes Myocet
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mary tumor >2 cm, rather than the timing of chemotherapy 
delivery.83,84
Our locoregional recurrence rate of 3.9% is low at the 
time of data cutoff.
A high percentage (61%–68%) of tumors that achieved 
CR, assessed using ultrasound and MRI, also demonstrated 
pCR. MRI has been reported as superior to ultrasound and 
mammography in the assessment of tumor extent and is 
highly sensitive in identifying residual disease following 
neoadjuvant treatment.85,86 We perceived a slight superiority 
of MRI in the current series.
pCR in HER2-positive breast cancer is associated with a 
substantially longer time to recurrence and death, as reported 
in a meta-analysis published by Broglio et al,40 which included 
a total of 5,500 HER2-positive breast cancer patients.
We demonstrated an association between pCR and 
improved DFS (P=0.19) in the current patients and a trend 
toward improved OS (P=0.068). This absence of a statistically 
significant benefit in OS could be explained by the low num-
ber of deaths at the time of analyses and to improvements in 
treatments for metastatic disease. None of the patients in the 
current series received pertuzumab in the neoadjuvant setting.
Concomitant administration of trastuzumab and classic 
anthracyclines is cardiotoxic and not permitted in clinical use.
In recent years, the incidence of congestive heart failure 
associated with trastuzumab and anthracyclines has become 
very low, since close monitoring of cardiac function and 
liposomal and less cardiotoxic anthracyclines have been 
used.11,43,48
We used two-dimensional echocardiography to monitor 
trastuzumab-related cardiotoxicity following the current 
clinical guidelines. This is a readily available cardiac imag-
ing modality with low cost and is radiation free. However, 
the current knowledge indicates that this technique does not 
accurately predict the development of cardiotoxicity. New 
imaging modalities can provide more information in the early 
stages and can quantify myocardial deformation as a marker 
of contractility. These new echocardiographic techniques, 
such as global longitudinal strain, can provide information 
that is predictive of cardiac dysfunction.87,88
Cardiac biomarkers, such as troponins and amino-
terminal fragment of brain natriuretic peptide, are also a 
useful tool to monitor cardiotoxicity. They have been studied 
as early predictors of cardiac damage in patients receiv-
ing anthracyclines and anti-HER2 therapy with disparate 
results.89,90
After a long follow-up period, our data showed a low 



























Figure 6 Basal lVeF at the end of chemotherapy and follow-up.
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neoadjuvant therapy in breast cancer
an asymptomatic decrease in LVEF and 0.64% demonstrated 
symptomatic ventricular dysfunction. Both cardiac events 
were related to other cardiovascular risk factors such as high 
BMI or high blood pressure and left breast radiotherapy.
This low incidence of cardiac events did not allow us 
to achieve statistically significant differences between the 
cardiotoxicity profiles of the chemotherapy treatments. The 
five patients who suffered a decline in LVEF <50% at the 
end of chemotherapy treatment had received concomitant 
 anthracyclines and trastuzumab instead of the sequential 
treatments.
Although the incidence of cardiotoxicity was low, it is 
desirable to avoid it through better selection of patients and 
the correction of cardiovascular risk factors (high BMI, arte-
rial hypertension, dyslipidemia) from the beginning, not only 
through diet and exercise but also using medication. The early 
administration of angiotensin–convertin–enzyme inhibitors 
(enalapril type) or beta-blockers (carvedilol or bisoprolol 
type) or a combination of both has produced improvements 
in cardiac function in breast cancer patients treated using 
anthracyclines. This highlights the need for collaboration 
between cardiologists and oncologists from the beginning 
of treatment.91–93
Conclusion
The sequence of a taxane and a less cardiotoxic anthracycline 
concomitant to trastuzumab was effective in the HER2 neoad-
juvant setting with high pCR and conservative breast surgery 
rates. Grade III and HR-negative tumors demonstrated the 
greatest benefit.
We observed a good correlation between the clinical 
complete response, as measured using ultrasound and MRI, 
and pCR.
We were able to associate pCR with improved DFS. 
Although there was a trend toward improved OS, it was not 
statistically significant.
The treatment was safe with an excellent long-term car-
diotoxicity profile.
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